Hematocrit and Stroke: A Forgotten and Neglected Link?

Seminars in Thrombosis and Hemostasis

Volumn 43, Issue 6, 2017, Pages 591-598

  Stavropoulos, Konstantinos ^a   Imprialos, Konstantinos P ^a   Bouloukou, Sofia ^a   Boutari, Chrysoula ^a   Doumas, Michael ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

blood viscosity; cerebrovascular disease; hematocrit; hyperviscosity; stroke

Indexed keywords

ARTICLE; BLOOD VISCOSITY; CEREBROVASCULAR ACCIDENT; HEMATOCRIT; HUMAN; HYPERTENSION; INDIVIDUALIZATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STROKE PATIENT; BLOOD; CEREBROVASCULAR DISEASE; METABOLISM; RISK ASSESSMENT; RISK FACTOR; SURVIVAL ANALYSIS;

HEMOGLOBIN;

CEREBROVASCULAR DISORDERS; HEMATOCRIT; HEMOGLOBINS; HUMANS; RISK ASSESSMENT; RISK FACTORS; STROKE; SURVIVAL ANALYSIS;

EID: 85020693156     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0037-1602663     Document Type: Article

References (81)

1. Donnan G. A. Fisher M. Macleod M. Davis S. M. Stroke. Lancet: 2008; 371 (9624): 1612 1623
2. Krishnamurthi R. V. Feigin V. L. Forouzanfar M. H., et al. Global Burden of Diseases, Injuries, Risk Factors Study 2010 (GBD 2010); GBD Stroke Experts Group. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health: 2013; 1 05 e259 e281
3. Mozaffarian D. Benjamin E. J. Go A. S., et al. Writing Group Members; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation: 2016; 133 04 e38 e360
4. Dhamoon M. S. Sciacca R. R. Rundek T. Sacco R. L. Elkind M. S. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology: 2006; 66 05 641 646
5. Kernan W. N. Ovbiagele B. Black H. R., et al. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke: 2014; 45 07 2160 2236
6. Thom T. Haase N. Rosamond W., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation: 2006; 113 06 e85 e151
7. O'Donnell M. J. Xavier D. Liu L., et al. INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet: 2010; 376 (9735): 112 123
8. Lowe G. D. Lee A. J. Rumley A. Price J. F. Fowkes F. G. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol: 1997; 96 01 168 173
9. Jeong S. K. Cho Y. I. Duey M. Rosenson R. S. Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment? Cardiovasc Drugs Ther: 2010; 24 02 151 160
10. Brun J. F. Bouchahda C. Chaze D. Benhaddad A. A. Micallef J. P. Mercier J. The paradox of hematocrit in exercise physiology: which is the normal range from an hemorheologist's viewpoint? Clin Hemorheol Microcirc: 2000; 22 04 287 303
11. Coull B. M. Beamer N. de Garmo P., et al. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke: 1991; 22 02 162 168
12. Imprialos K. P. Boutari C. Stavropoulos K. Doumas M. Karagiannis A. I. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality? J Neurol Neurosurg Psychiatry: 2017; 88 03 249 253
13. Zinman B. Wanner C. Lachin J. M., et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med: 2015; 373 22 2117 2128
14. Wu J. H. Foote C. Blomster J., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol: 2016; 4 05 411 419
15. Lowe G. D. Forbes C. D. Blood rheology and thrombosis. Clin Haematol: 1981; 10 02 343 367
16. Schwartz C. J. Valente A. J. Sprague E. A. Kelley J. L. Nerem R. M. The pathogenesis of atherosclerosis: an overview. Clin Cardiol: 1991; 14 02 01 I1 I16
17. Liepsch D. Moravec S. Pulsatile flow of non-Newtonian fluid in distensible models of human arteries. Biorheology: 1984; 21 04 571 586
18. Koenig W. Ernst E. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis: 1992; 94 (2-3): 93 107
19. Dormandy J. A. Medical and engineering problems of blood viscosity. Biomed Eng: 1974; 9 07 284 289
20. Lowe G. D. Blood rheology in arterial disease. Clin Sci (Lond): 1986; 71 02 137 146
21. Turitto V. T. Weiss H. J. Platelet and red cell involvement in mural thrombogenesis. Ann N Y Acad Sci: 1983; 416 363 376
22. Cecchi E. Marcucci R. Poli D., et al. Hyperviscosity as a possible risk factor for cerebral ischemic complications in atrial fibrillation patients. Am J Cardiol: 2006; 97 12 1745 1748
23. Fung Y. C. Biomechanics: Mechanical Properties of Living Tissues. New York Springer-Verlag: 1981; 108 113
24. Gachtgens P. Pries A. R. Ley K. Structural hemodynamic and rheological characteristics of blood flow in the circulation. In: Chein S. Dormandy J. Ernst E. Matrai A., eds. Clinical Hemorheology: Applications in Cardiovascular and Haematological Disease, Diabetes, Surgery, and Gynecology. Boston, MA Martinus Nijhoff: 1987; 97 124
25. Leonhardt H. Arntz H. R. Klemens U. H. Studies of plasma viscosity in primary hyperlipoproteinaemia. Atherosclerosis: 1977; 28 01 29 40
26. Seplowitz A. H. Chien S. Smith F. R. Effects of lipoproteins on plasma viscosity. Atherosclerosis: 1981; 38 (1-2): 89 95
27. Rosenson R. S. Baker A. L. Chow M. J. Hay R. V. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis. Gastroenterology: 1990; 98 (5, Pt 1): 1351 1357
28. Kwaan H. C. Bongu A. The hyperviscosity syndromes. Semin Thromb Hemost: 1999; 25 02 199 208
29. Kwaan H. C. Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost: 2003; 29 05 451 458
30. Li R. Y. Cao Z. G. Li Y. Wang R. T. Increased whole blood viscosity is associated with silent cerebral infarction. Clin Hemorheol Microcirc: 2015; 59 04 301 307
31. Ernst E. Resch K. L. Matrai A. Buhl M. Schlosser P. Paulsen H. F. Impaired blood rheology: a risk factor after stroke? J Intern Med: 1991; 229 05 457 462
32. Levy B. I. Schiffrin E. L. Mourad J. J., et al. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation: 2008; 118 09 968 976
33. Fukuda S. Yasu T. Kobayashi N. Ikeda N. Schmid-Schönbein G. W. Contribution of fluid shear response in leukocytes to hemodynamic resistance in the spontaneously hypertensive rat. Circ Res: 2004; 95 01 100 108
34. Tamariz L. J. Young J. H. Pankow J. S., et al. Blood viscosity and hematocrit as risk factors for type 2 diabetes mellitus: the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol: 2008; 168 10 1153 1160
35. Frangos S. G. Gahtan V. Sumpio B. Localization of atherosclerosis: role of hemodynamics. Arch Surg: 1999; 134 10 1142 1149
36. Malek A. M. Alper S. L. Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA: 1999; 282 21 2035 2042
37. Lee A. J. Mowbray P. I. Lowe G. D. Rumley A. Fowkes F. G. Allan P. L. Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation: 1998; 97 15 1467 1473
38. Ernst E. Weihmayr T. Schmid M. Baumann M. Matrai A. Cardiovascular risk factors and hemorheology. Physical fitness, stress and obesity. Atherosclerosis: 1986; 59 03 263 269
39. Lowe G. D. Drummond M. M. Forbes C. D. Barbenel J. C. The effects of age and cigarette-smoking on blood and plasma viscosity in men. Scott Med J: 1980; 25 01 13 17
40. Coppola L. Caserta F. Guastafierro S., et al. De Lucia D. Blood viscosity and aging. Arch Gerontol Geriatr: 2000; 31 01 35 42
41. Devereux R. B. Case D. B. Alderman M. H. Pickering T. G. Chien S. Laragh J. H. Possible role of increased blood viscosity in the hemodynamics of systemic hypertension. Am J Cardiol: 2000; 85 10 1265 1268
42. Fowkes F. G. Lowe G. D. Rumley A. Lennie S. E. Smith F. B. Donnan P. T. The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J: 1993; 14 05 597 601
43. Smith W. C. Lowe G. D. Lee A. J. Tunstall-Pedoe H. Rheological determinants of blood pressure in a Scottish adult population. J Hypertens: 1992; 10 05 467 472
44. Levenson J. Simon A. C. Cambien F. A. Beretti C. Cigarette smoking and hypertension. Factors independently associated with blood hyperviscosity and arterial rigidity. Arteriosclerosis: 1987; 7 06 572 577
45. Letcher R. L. Chien S. Pickering T. G. Sealey J. E. Laragh J. H. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration. Am J Med: 1981; 70 06 1195 1202
46. Sloop G. D. Garber D. W. The effects of low-density lipoprotein and high-density lipoprotein on blood viscosity correlate with their association with risk of atherosclerosis in humans. Clin Sci (Lond): 1997; 92 05 473 479
47. Rosenson R. S. McCormick A. Uretz E. F. Distribution of blood viscosity values and biochemical correlates in healthy adults. Clin Chem: 1996; 42 (8, Pt 1): 1189 1195
48. de Simone G. Devereux R. B. Chien S. Alderman M. H. Atlas S. A. Laragh J. H. Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. Circulation: 1990; 81 01 107 117
49. Rosenson R. S. Shott S. Tangney C. C. Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. Atherosclerosis: 2002; 161 02 433 439
50. Stamos T. D. Rosenson R. S. Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis: 1999; 146 01 161 165
51. Hoieggen A. Fossum E. Moan A. Enger E. Kjeldsen S. E. Whole-blood viscosity and the insulin-resistance syndrome. J Hypertens: 1998; 16 02 203 210
52. Lowe G. D. Blood viscosity, lipoproteins, and cardiovascular risk. Circulation: 1992; 85 06 2329 2331
53. Jax T. W. Peters A. J. Plehn G. Schoebel F. C. Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes - a two year follow-up of 243 patients. Cardiovasc Diabetol: 2009; 8 48
54. Cho Y. I. Mooney M. P. Cho D. J. Hemorheological disorders in diabetes mellitus. J Diabetes Sci Technol: 2008; 2 06 1130 1138
55. Carroll S. Cooke C. B. Butterly R. J. Plasma viscosity, fibrinogen and the metabolic syndrome: effect of obesity and cardiorespiratory fitness. Blood Coagul Fibrinolysis: 2000; 11 01 71 78
56. Ernst E. Koenig W. Matrai A. Filipiak B. Stieber J. Blood rheology in healthy cigarette smokers. Results from the MONICA project, Augsburg. Arteriosclerosis: 1988; 8 04 385 388
57. Ernst E. Haemorheological consequences of chronic cigarette smoking. J Cardiovasc Risk: 1995; 2 05 435 439
58. Purves W. K. Sadava D. Orians G. H. Heller H. Life: The Science of Biology, 7th ed. Sunderland, MA Sinauer Associates: 2004
59. Grotta J. Ackerman R. Correia J. Fallick G. Chang J. Whole blood viscosity parameters and cerebral blood flow. Stroke: 1982; 13 03 296 301
60. Thomas D. J. Marshall J. Russell R. W., et al. Effect of haematocrit on cerebral blood-flow in man. Lancet: 1977; 2 (8045): 941 943
61. Häggendal E. Nilsson N. J. Norbäck B. Rheological aspects of cerebral blood flow and oxygen consumption. An experimental study in dogs. Acta Chir Scand Suppl: 1966; 364 1 49
62. Willison J. R. Thomas D. J. du Boulay G. H., et al. Effect of high haematocrit on alertness. Lancet: 1980; 1 (8173): 846 848
63. Chievitz E. Thiede T. Complications and causes of death in polycythaemia vera. Acta Med Scand: 1962; 172 513 523
64. Millikan C. H. Siekert R. G. Whisnant J. P. Intermittent carotid and vertebral-basilar insufficiency associated with polycythemia. Neurology: 1960; 10 188 196
65. Stone H. O. Thompson H. K. Jr. Schmidt-Nielsen K. Influence of erythrocytes on blood viscosity. Am J Physiol: 1968; 214 04 913 918
66. Drüeke T. B. Locatelli F. Clyne N., et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med: 2006; 355 20 2071 2084
67. Singh A. K. Szczech L. Tang K. L., et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med: 2006; 355 20 2085 2098
68. Besarab A. Bolton W. K. Browne J. K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med: 1998; 339 09 584 590
69. Pfeffer M. A. Burdmann E. A. Chen C. Y., et al. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med: 2009; 361 21 2019 2032
70. Lippi G. Franchini M. Favaloro E. J. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost: 2010; 36 05 537 549
71. Unger E. F. Thompson A. M. Blank M. J. Temple R. Erythropoiesis-stimulating agents - time for a reevaluation. N Engl J Med: 2010; 362 03 189 192
72. Gordon T. Sorlie P. Kannel W. B. Coronary Heart Disease, Atherothrombotic Brain Infraction, Intermittent Claudication-A Multivariable Analysis of Some Factors Related to Their Incidence: Framingham Study, 16-Year Follow-up. Washington, DC US Government Printing Office: 1971
73. Kannel W. B. Gordon T. Wolf P. A. McNamara P. Hemoglobin and the risk of cerebral infarction: the Framingham Study. Stroke: 1972; 3 04 409 420
74. Tohgi H. Yamanouchi H. Murakami M. Kameyama M. Importance of the hematocrit as a risk factor in cerebral infarction. Stroke: 1978; 9 04 369 374
75. Kiyohara Y. Ueda K. Hasuo Y., et al. Hematocrit as a risk factor of cerebral infarction: long-term prospective population survey in a Japanese rural community. Stroke: 1986; 17 04 687 692
76. Lowe G. D. Jaap A. J. Forbes C. D. Relation of atrial fibrillation and high haematocrit to mortality in acute stroke. Lancet: 1983; 1 (8328): 784 786
77. Gagnon D. R. Zhang T. J. Brand F. N. Kannel W. B. Hematocrit and the risk of cardiovascular disease - the Framingham study: a 34-year follow-up. Am Heart J: 1994; 127 03 674 682
78. Wannamethee G. Perry I. J. Shaper A. G. Haematocrit, hypertension and risk of stroke. J Intern Med: 1994; 235 02 163 168
79. Sacco S. Marini C. Olivieri L. Pistoia F. Carolei A. Contribution of hematocrit to early mortality after ischemic stroke. Eur Neurol: 2007; 58 04 233 238
80. Gotoh S. Hata J. Ninomiya T., et al. Hematocrit and the risk of cardiovascular disease in a Japanese community: The Hisayama Study. Atherosclerosis: 2015; 242 01 199 204
81. Turcato G. Cappellari M. Follador L., et al. Red blood cell distribution width is an independent predictor of outcome in patients undergoing thrombolysis for ischemic stroke. Semin Thromb Hemost: 2017; 43 01 30 35